Thalidomide as an emerging immunotherapeutic agent

Immunol Today. 1999 Dec;20(12):538-40. doi: 10.1016/s0167-5699(99)01531-5.
No abstract available

Publication types

  • Review

MeSH terms

  • Abnormalities, Drug-Induced / etiology
  • Acquired Immunodeficiency Syndrome / therapy
  • Adjuvants, Immunologic / therapeutic use*
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Drug Design
  • Erythema Nodosum / etiology
  • Erythema Nodosum / therapy
  • Humans
  • Immunotherapy / methods*
  • Leprosy, Lepromatous / complications
  • Neoplasms / therapy
  • Neovascularization, Pathologic / therapy
  • Th2 Cells / drug effects
  • Th2 Cells / metabolism
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Adjuvants, Immunologic
  • Anti-Inflammatory Agents, Non-Steroidal
  • Tumor Necrosis Factor-alpha
  • Thalidomide